The administrative core is responsible for the operation of the program and supervision of the conduct of the proposed grant. The core facilitates communication between investigators and visits of outside investigators to MD Anderson Cancer Center. The core maintains the central databases for the clinical and translational research described in the projects as well as the GMP - Immune Assessment Core (Core E). The core supports the FDA IND submissions and reporting required for protocols in the POI. The core manages program personnel and budgets for each section ofthe grant. The core is responsible for preparing reports for the research projects and publications. The CML group meets multiple times per week in meeting related to leukemias, stem cell transplantation and specific laboratory research related to this program. We discuss the design, status and results of clinical and laboratory research, sample acquisition, status of patients participating on clinical research studies, pathology, cytogenetic, molecular analysis review. This includes a weekly CML POI program meetings and broader meetings involving the Leukemia, Stem Cell Transplant and Cellular Therapy (SCTCT) and Molecular Pathology programs. Specifically, the Administrative Core has the following objectives to accomplish: ? Provide leadership to and oversight of the cores and research projects ofthe Program. ? Convene all necessary meetings, including meetings ofthe External Scientific Advisory Board, regularly scheduled meetings of the investigators, and discussion of all the clinical trials in the program. ? Prepare grant continuation submissions for the NCI and to comply with internal reporting requirements. ? Coordinate data quality control and quality assurance in conjunction with the Biostatistics and other projects and cores. ? Monitor and control expenditures and maintain budget information. ? Track and maintain record of all publications, including abstracts and manuscripts, resulting from the program project.

Public Health Relevance

The administrative core oversees this CML program project grant under the leadership of Dr. Champlin. Core A monitors the progress from each project and core and ensure the proper use of funding. Core A also supervises the conduct of clinical research and ascertain the regulatory compliance and HIPAA regulations are followed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-23
Application #
8513792
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
23
Fiscal Year
2013
Total Cost
$292,492
Indirect Cost
$103,640
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105

Showing the most recent 10 out of 375 publications